Two pharmaceutical companies - Merck & Co Inc. and Pfizer Inc. - have just announced that they have partnered up for the development of the type 2 diabetes drug ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor... via Featured Health News from Medical News Today Read More Here..
No comments:
Post a Comment